Does the use of a wearable cardioverter-defibrillator (WCD) prevent sudden cardiac death in patients with newly diagnosed NICM and LVEF ≤35%?
Patients with newly diagnosed NICM and severely reduced LVEF have an elevated risk of VT/VF during early therapy optimization, supporting the consideration of WCD to prevent sudden cardiac death.
Patients with newly diagnosed NICM and LVEF ≤35% show an elevated risk of ventricular tachycardia/fibrillation during initiation and optimization of heart failure therapy. To prevent sudden cardiac death, WCD should be considered in patients with newly diagnosed NICM with severely reduced LVEF.
Duncker et al. (Thu,) studied this question.